Plenary Session 4: 
Roundtable of pharma and academic experts: 
Overcoming resistance through combined therapies

Moderator: Richard L. Schilsky, 
MD, FASCO 
Chief Medical Officer, ASCO 
Chairman, WIN SAB
Discussants

Pharma experts
- Richard E. Buller, Pfizer Oncology, USA
- Katherine Galvin, Takeda Pharmaceuticals International, USA
- Antoine Yver, AstraZeneca, USA

Academic experts
- Alexander Eggermont, Gustave Roussy, France
- Waun Ki Hong, University of Texas, MD Anderson Cancer Center, USA
- Razelle Kurzrock, University of California, San Diego, USA
- John Mendelsohn, University of Texas, MD Anderson Cancer Center, USA
- Jean-Charles Soria, Gustave Roussy, France
Questions to Consider

• If we agree that combination therapies will be necessary to overcome drug resistance, how do we determine the specific drug combination likely to be effective for an individual patient?

• Given the capacity of most cancers to evolve in response to the selection pressure of treatment, how many drugs in combination are likely to be necessary to gain long term tumor control? Will patients be able to tolerate and afford long-term combination treatment?
Questions to Consider

• As multi-drug combinations can have a large number of potential drug doses and schedules, how do we determine the optimal dosing strategies for drug combinations?
• What is the best way to combine drugs that inhibit specific oncogene-driven pathways with agents that modulate the immune response to the tumor?
• What approaches is your organization taking to develop combination therapies for cancer?